RUNX3 and non-small cell lung carcinoma: Further stratification analyses based on pathologic staging indicated that RUNX3/H3K27me3 co-expression might define some specific early-stage patient group (pTNM-I) so as to achieve good outcome and better survival after radical surgery and thereafter could be used as a good biomarker in the postoperative NSCLC patients.